Upload Records Snowball Search Search OpenAlex
About the database ScholarIQanswers from OpenAlex & ORCID
How has Paul Lorigan's publication output changed over time?
ScholarIQpublication output · 2010–2015
Output grew100% over the shown period — from 1 works in 2010 to 2 in 2015.
1
1
2
201020112015
What are the most-cited papers on Paul Lorigan?
ScholarIQmost cited works
Improved Survival with Ipilimumab in Patients with Metastatic Melanoma
F. Stephen Hodi, Steven O’Day, David F. McDermott, Robert Weber, Jeffrey A. Sosman, John B.A.G. Haanen, René González, Caroline Robert, Dirk Schadendorf, Jessica C. Hassel, Wallace Akerley, Alfons J.M. van den Eertwegh, Jose Lutzky, Paul Lorigan, Julia Vaübel, Gerald P. Linette, David Hogg, Christian H. Ottensmeier, Célèste Lebbé, Christian Peschel, Ian Quirt, Joseph I. Clark, Jedd D. Wolchok, Jeffrey S. Weber, Jason Tian, Michael Yellin, Geoffrey Nichol, Axel Hoos, Walter J. Urba
New England Journal of Medicine. 201015,211 CitationsOPEN ACCESS
Improved Survival with Vemurafenib in Melanoma with BRAF V600E Mutation
Paul B. Chapman, Axel Hauschild, Caroline Robert, John B.A.G. Haanen, Paolo A. Ascierto, James Larkin, Reinhard Dummer, Claus Garbe, Alessandro Testori, Michele Maio, David Hogg, Paul Lorigan, Célèste Lebbé, Thomas Jouary, Dirk Schadendorf, Antoni Ribas, Steven O’Day, Jeffrey A. Sosman, John M. Kirkwood, Alexander M.M. Eggermont, Brigitte Dréno, K. B. Nolop, Jiang Li, B. Nelson, Jeannie Hou, Richard J. Lee, Keith T. Flaherty, Grant A. McArthur
New England Journal of Medicine. 20117,715 CitationsOPEN ACCESS
Pembrolizumab versus Ipilimumab in Advanced Melanoma
Caroline Robert, Jacob Schachter, Georgina V. Long, Ana Arance, Jean‐Jacques Grob, Laurent Mortier, Adil Daud, Matteo S. Carlino, Catriona M. McNeil, Michal Lotem, James Larkin, Paul Lorigan, Bart Neyns, Christian U. Blank, Omid Hamid, Christine Mateus, Ronnie Shapira‐Frommer, Michele Kosh, Honghong Zhou, Nageatte Ibrahim, Scot Ebbinghaus, Antoni Ribas
New England Journal of Medicine. 20155,885 CitationsOPEN ACCESS
Nivolumab versus chemotherapy in patients with advanced melanoma who progressed after anti-CTLA-4 treatment (CheckMate 037): a randomised, controlled, open-label, phase 3 trial
Jeffrey S. Weber, Sandra P. D’Angelo, David R. Minor, F. Stephen Hodi, Ralf Gutzmer, Bart Neyns, Christoph Höeller, Nikhil I. Khushalani, Wilson H. Miller, Christopher D. Lao, Gerald P. Linette, L. Thomas, Paul Lorigan, Kenneth F. Grossmann, Jessica C. Hassel, Michele Maio, Mario Sznol, Paolo A. Ascierto, Peter Mohr, Bartosz Chmielowski, Alan H. Bryce, Inge Marie Svane, Jean‐Jacques Grob, Angela M. Krackhardt, Christine E. Horak, Alexandre Lambert, Arvin Yang, James Larkin
The Lancet Oncology. 20152,672 Citations
Related on ScholarIQ
Improved Survival with Ipilimumab in Patients with Metastatic Melanoma
Paper
Improved Survival with Vemurafenib in Melanoma with BRAF V600E Mutation
Paper
Pembrolizumab versus Ipilimumab in Advanced Melanoma
Paper
Nivolumab versus chemotherapy in patients with advanced melanoma who progressed after anti-CTLA-4 treatment (CheckMate 037): a randomised, controlled, open-label, phase 3 trial
Paper
Cancer Immunotherapy and Biomarkers
Topic
CAR-T cell therapy research
Topic